EP4185288A4 - Agents thérapeutiques et utilisations de ceux-ci - Google Patents

Agents thérapeutiques et utilisations de ceux-ci Download PDF

Info

Publication number
EP4185288A4
EP4185288A4 EP20946050.0A EP20946050A EP4185288A4 EP 4185288 A4 EP4185288 A4 EP 4185288A4 EP 20946050 A EP20946050 A EP 20946050A EP 4185288 A4 EP4185288 A4 EP 4185288A4
Authority
EP
European Patent Office
Prior art keywords
therapeutic agents
therapeutic
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20946050.0A
Other languages
German (de)
English (en)
Other versions
EP4185288A1 (fr
Inventor
Gene H. Zaid
Thomas W. Burgoyne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ankh Life Sciences Ltd
Original Assignee
Ankh Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ankh Life Sciences Ltd filed Critical Ankh Life Sciences Ltd
Publication of EP4185288A1 publication Critical patent/EP4185288A1/fr
Publication of EP4185288A4 publication Critical patent/EP4185288A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP20946050.0A 2020-07-21 2020-07-21 Agents thérapeutiques et utilisations de ceux-ci Pending EP4185288A4 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2020/042933 WO2022019892A1 (fr) 2020-07-21 2020-07-21 Agents thérapeutiques et utilisations de ceux-ci

Publications (2)

Publication Number Publication Date
EP4185288A1 EP4185288A1 (fr) 2023-05-31
EP4185288A4 true EP4185288A4 (fr) 2024-04-24

Family

ID=79729760

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20946050.0A Pending EP4185288A4 (fr) 2020-07-21 2020-07-21 Agents thérapeutiques et utilisations de ceux-ci

Country Status (3)

Country Link
EP (1) EP4185288A4 (fr)
CN (1) CN115916195A (fr)
WO (1) WO2022019892A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101367802A (zh) * 2008-09-27 2009-02-18 暨南大学 苦木中的β-卡巴林类生物碱及其制备方法和用途
WO2009047298A2 (fr) * 2007-10-12 2009-04-16 Bioalliance Pharma Dimères de harmol ou de ses dérivés et leurs utilisations
WO2021026016A1 (fr) * 2019-08-05 2021-02-11 Ankh Life Sciences Limited Dimères polycycliques fusionnés

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4631323A (en) * 1985-07-29 1986-12-23 Honeywell Inc. Method of making conducting polymer complexes of N-substituted carbazoles and substituted benzaldehydes
AU2001274827A1 (en) * 2000-05-09 2001-11-20 The Regents Of The University Of California Porphyrin-based neutron capture agents for cancer therapy
US9907786B2 (en) * 2014-10-21 2018-03-06 Ions Pharmaceutical S.À R.L. Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009047298A2 (fr) * 2007-10-12 2009-04-16 Bioalliance Pharma Dimères de harmol ou de ses dérivés et leurs utilisations
CN101367802A (zh) * 2008-09-27 2009-02-18 暨南大学 苦木中的β-卡巴林类生物碱及其制备方法和用途
WO2021026016A1 (fr) * 2019-08-05 2021-02-11 Ankh Life Sciences Limited Dimères polycycliques fusionnés

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHEN XIAOFEI ET AL: "Design, Synthesis, and Biological Evaluation of Novel N-Acylhydrazone Bond Linked Heterobivalent [beta]-Carbolines as Potential Anticancer Agents", MOLECULES, vol. 24, no. 16, 1 August 2019 (2019-08-01), DE, pages 2950, XP055901185, ISSN: 1433-1373, DOI: 10.3390/molecules24162950 *
GUO LIANG ET AL: "Synthesis and biological evaluation of novel N 9 -heterobivalent [beta]-carbolines as angiogenesis inhibitors", JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, vol. 34, no. 1, 1 January 2019 (2019-01-01), GB, pages 375 - 387, XP093007443, ISSN: 1475-6366, DOI: 10.1080/14756366.2018.1497619 *
See also references of WO2022019892A1 *

Also Published As

Publication number Publication date
WO2022019892A1 (fr) 2022-01-27
EP4185288A1 (fr) 2023-05-31
CN115916195A (zh) 2023-04-04

Similar Documents

Publication Publication Date Title
EP3920923A4 (fr) Agents thérapeutiques et méthodes de traitement
EP4087840A4 (fr) Inhibiteurs de mek et leurs utilisations thérapeutiques
EP4003401A4 (fr) Compositions et procédés comprenant des agents thérapeutiques activés par protéase
EP3960766A4 (fr) Agent thérapeutique anti-tumeur et son utilisation
EP3986397A4 (fr) Agents de dégradation de hck et leurs utilisations
EP4110066A4 (fr) Formulations et leurs utilisations
EP4121031A4 (fr) 3-diarylméthylènes et leurs utilisations
EP3999092A4 (fr) Agents et méthodes de polythérapie contre le cancer
EP3919472A4 (fr) Dérivé de dézocine et son utilisation médicale
EP3787639A4 (fr) Utilisation et méthodes thérapeutiques
EP4140480A4 (fr) Combinaison de médicaments et son utilisation
EP4129283A4 (fr) Association pharmaceutique et son utilisation
EP4185288A4 (fr) Agents thérapeutiques et utilisations de ceux-ci
EP4164619A4 (fr) Méthodes de traitement et formulations
AU2021901067A0 (en) Therapeutic agents and uses therefor
AU2020901994A0 (en) Therapeutic agents and uses therefor
EP3993874A4 (fr) Agents de liaison à cd38 et leurs utilisations
EP3993818A4 (fr) Agent de liaison à cd38 et utilisations associées
EP3960242A4 (fr) Conjugué et agent thérapeutique contre le cancer
EP4021906A4 (fr) Dérivés de n-(2-aminophényl)-prop-2-énamide, et leurs utilisations dans le traitement d'un cancer
AU2020901854A0 (en) Therapeutic methods and agents
AU2020901800A0 (en) Therapeutic methods and agents
EP3941450A4 (fr) Antihistaminiques administrés par voie intranasale et utilisations associées
EP4097223A4 (fr) Agents de liaison à strad et leurs utilisations
AU2023903793A0 (en) Combination therapy and uses thereof

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20221208

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20240327

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 471/12 20060101ALI20240321BHEP

Ipc: A61K 31/11 20060101ALI20240321BHEP

Ipc: A61K 31/437 20060101AFI20240321BHEP